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ABSTRACT
This paper describes the UK Research Ethics Committee’s 
(REC) preparations and review of the global first SARS- 
CoV- 2 human infection challenge studies. To frame 
our review, we used the WHO guidance and our UK 
Health Research Authority ethical review framework. The 
WHO criteria covered most issues we were concerned 
about, but we would recommend one further criterion 
directing RECs to consider alternative research designs. 
Could research questions be equally well answered 
by less intrusive studies? The committee met virtually, 
ensuring broad representation across the UK nations 
and also ensuring applicants could attend easily. We 
worked in collaboration with the applicants but while we 
recognise that such proximity might raise the accusation 
of ’collusion’, we made every effort to maintain ’moral 
distance’ and all decisions were made by the committee 
alone. Prior existing processes and policy facilitated 
training and review but even with this preparation, 
review took time and this could have hindered a rapid 
response to the emergency. Review for the various 
follow- on studies will now be speedier and once the 
pandemic has subsided, our group could be reconvened 
in future emergencies. In conclusion, we have tried 
to make decisions in good faith. We know there is 
controversy and disagreement and reasonable people 
may feel we have made the wrong decision. A more 
detailed analysis, built on the WHO guidance, is provided 
in online supplemental material.
PREPARATION
International guidance and national law require 
research proposals to be reviewed by an indepen-
dent research ethics committee (REC), so when the 
UK government announced its support for SARS- 
CoV- 2 human infection challenge studies (HICS), 
the UK Health Research Authority (HRA) convened 
a specialist ad hoc REC to undertake ethical review.
Expert and lay members of UK RECs recognised 
to review Clinical Trials of Investigational Medic-
inal Products or phase I studies in healthy volun-
teers, particularly those with experience of vaccine 
studies, were invited to join the ad hoc REC. They 
were then asked to attend two virtual HRA work-
shops before the first committee meeting.
These training meetings provided an opportunity 
for members to meet, discuss collective views and 
their approach to review. The first provided a back-
ground to HICS, while the second was designed to 
help the committee think through the questions that 
should be asked when reviewing SARS- CoV- 2 HICS 
and the considerations that would then arise (to 
consider ‘how to think’ rather than ‘what to think’). 
To facilitate this, an Oxford debate entitled ‘This 
house believes that SARS CoV2 human challenge 
studies are inherently unethical’ was conducted 
and after this, delegates reviewed a ‘dummy’ SARS- 
CoV- 2 HICS as if in committee. Members were 
provided with articles from both sides of the argu-
ment for further reading.
REVIEW
We conducted our review using all resources avail-
able to us. We saw we could not, nor should not, 
work alone. Given the controversial nature of the 
study, it was essential that the design and review had 
meaningful and robust involvement of all with legit-
imate interest, both expert and lay (WHO criteria 3 
and 4).1 We were pleased to note the detailed public 
involvement the research team had undertaken.
We also realised very rapidly that, given the 
possible risks and burdens to the volunteers, we had 
to consider alternative research designs in depth. In 
essence we had to review more than one proposal. 
We asked, ‘could studies of natural infection (field 
studies) answer research questions more safely and 
as reliably as an HICS?’ To help us reach a deci-
sion, we wanted to know the exact data both types 
of studies would generate (benefits), their risks 
(harms) and how each would link to prevention and 
treatment of SARS- CoV- 2 infection. With this we 
could base our decision on such a comparison.
Benefits and harms (WHO criteria 1 and 2)
The balance between benefits and harms was at the 
centre of our review. The benefits would need to 
be robust and valid answers to well defined, justi-
fied research questions. To ensure that this purpose 
would be met, we sought reassurance that the ques-
tions were indeed justified from expert and public 
groups and that the study methods would provide 
meaningful and valid answers through methodolog-
ical and statistical analysis.
The first HICS we reviewed was to define the 
dose infectivity for further SARS- CoV- 2 studies 
with wider therapeutic aims. Its acceptability, there-
fore, depended crucially on demonstrating purpose 
to these later studies. It could not stand on its own 
so we wanted to know exactly how these later 
projects would contribute to the understanding 
of SARS- CoV- 2 infection, investigating correlates 
of immunity, vaccine development, public health 
management and advancing improvements in 
treatments.
We also wanted to be reassured that:
 ► The results could be generalised from these 
healthy volunteers to the broader population.
 ► Whether the studies were justified when there 
were vaccines of greater than 90% efficacy.
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 ► These studies would continue to have value as new variants 
emerge.
Possible harms and their mitigation were the other part 
of this balance, not a unique consideration for HICS but of 
particular importance as volunteers could potentially be very 
sick. We looked closely at quantitative data on the risk of 
hospitalisation, admission to critical care, death and ‘long 
COVID- 19’ (2- 3).2–4 When assessing the proposed measures 
to mitigate risk, we considered the proposed care and rescue 
treatments along with the expertise and experience of the 
whole team, both those conducting the research and those 
who would be caring for the volunteers.
Much discussion was given to the proposed rescue medication, 
remdesivir. We felt that the balance between the risks of SARS- 
CoV- 2 infection and this treatment needed detailed consider-
ation, particularly as there was extremely limited evidence for 
its efficacy in groups such as of these volunteers although we 
recognised that it was well tolerated in young people. There 
were hypothetical reasons for its use but no convincing data. We 
also explored whether the use of this medication would under-
mine the purpose of the research.
Given the pandemic surge that was happening when we 
reviewed the study, we considered whether it would be more 
appropriate to delay therecruitment until there was guaranteed 
critical care availability should the volunteers become ill.
Selection and consent (WHO criteria 6 and 8)
The applicants proposed using the qCOVID personal risk assess-
ment tool (https:// qcovid. org/) to ensure that volunteers would 
be at the least risk from SARS- CoV- 2 infection. We accepted 
this after much discussion but, while recognising the increased 
vulnerability of BAME individuals (Black, Asian and Minority 
Ethnic - a demographic classification), we were also keen that 
they should not be discriminated against and unfairly excluded 
from participation.
Given the possible risks of harm, we saw robust consent 
procedures would be of crucial importance5. It would be vital 
to ensure any volunteer understood what he or she was agreeing 
to and the attendant risks. To ensure this, we required a clear 
consenting schedule, starting with an introduction to outline the 
key facts about the study followed by a more detailed discus-
sion in which the participant information sheet could be used 
as a template for discussion with the participant. After a break 
allowing the potential participant to reflect and ask others, 
understanding would be checked by a consent quiz before signed 
consent was taken using an itemised informed consent form, 
matched to the introductory ‘key facts’. We required this process 
was audio or video recorded.
DISCUSSION
We have now completed the review of one further SARS- CoV- 2 
human challenge study. Both were given a provisional opinion at 
the first meeting, then favourable after amendments were made 
and accepted. No vote was taken but dissenting voices on issues 
were recorded. Those who dissented accepted the committee’s 
decision.
To frame our review, we used established guidance1 and 
the UK HRA ethical review framework.6 We found the WHO 
criteria a useful basis for deliberation, covering most of the issues 
we were concerned about and only two did not map well onto 
our UK framework, but these were more about the process of 
review rather the ethical/scientific considerations (criterion 4, 
‘Coordination’ and criterion 7, ‘Expert Review’). These could 
be considered as being covered by the formation of the specialist 
REC by the HRA. After our review, we would now recommend 
one further criterion, specifically directing RECs to ask and 
consider alternative research designs. This was a major consider-
ation for us. Could research questions be equally well answered 
by less intrusive field studies?
Given the pandemic lockdown, we met virtually. This had 
benefit, ensuring broad representation across the UK nations and 
that applicants were easily able to attend. We were unanimous 
in our view that discussing the project with the applicants at the 
meeting was essential to our review. As just three examples, the 
use of remdesivir as a rescue medication, the evaluation of alter-
native designs and developing robust consent processes required 
discussion with the researchers over more than one meeting (and 
correspondence between these).
We worked in collaboration with the applicants and we 
recognise that such proximity might raise the accusation of 
‘collusion’. We made every effort to maintain ‘moral distance’ 
and all decisions were made by the committee alone. As an 
example, when we felt consent procedures were inadequate, 
the committee proposed one member should engage with 
the team to describe our concerns and suggestions. This was 
recorded in the minutes and the member took limited part in 
the subsequent debate and would not have participated if a 
vote had to be called.
What might we have done differently?
Even with prior preparation, review took time and, in the context 
of a pandemic where there is an argument for speed, this could 
have hindered a rapid response to the emergency. We need to 
continue to consider how our review might be conducted more 
speedily and streamlined for future emergencies.
Now the committee is established, we hope review for the 
various follow- on studies will be speedier and with time our 
procedures can be further refined and if we are ‘mothballed’ 
once the pandemic has subsided, our group could be reconvened 
in future emergencies.
In conclusion, we have tried to make a decision in good faith, 
using the evidence we could ascertain and listening to all others 
with fair interest. We know there is controversy and disagree-
ment within and without our committee and reasonable people 
may feel we have made the wrong decision but we feel we have 
given the issue detailed consideration. We cannot know whether 
the possible benefits outweigh the risks but we will require 
regular reports. Meanwhile this article is an opportunity for us 
to hear other voices in this area. A detailed analysis is provided 
in the online supplemental material.
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Deliberations structured on the WHO guidance.  
1. Scientific justification  
“SARS CoV-2 challenge studies must have strong scientific justification.” 
Questions and deliberations  
i. What are the research questions and purposes? 
ii. Why is it important to seek answers to these questions? 
iii. Have these questions been answered already? 
iv. Will the chosen method answer the questions and contribute meaningful and valid 
information that will help disease prevention, management and treatment? 
v. Will results be applicable to the broader community (generalizability)? 
vi. Might the study detract from pandemic care? 
vii. How has transparency been ensured so results will be rapidly available? 
viii. Has there been independent review? 
ix. Has there been public involvement? 
 
i. What are the research questions and purposes? The applicants answered:-  
“20/UK/0002 is a dose finding, enabling study to develop a SARS COV 2 human 
challenge model.” 
The committee accepted this position in conjunction with 1(ii).  
ii. Why is it important to seek answers? 
The committee felt this first, dose finding, study to be of extremely limited, if any, 
value. However if it were to enable future studies with possible benefit, there could be 
acceptable purpose. Hence, the committee wanted to know the exact data that these 
later studies would generate and how each would link to prevention and treatment of 
SARS COV 2 infection. 
The applicants proposed further studies would: - 
a) Establish the incubation period. 
“The “incubation period” of COVID-19 is the time from coronavirus exposure to the 
beginning of symptoms and when people are most infectious. This human 
challenge study is the only way to accurately know how long the incubation period 
is and will be essential to improve Track and Trace efforts. 
b) Allow study of asymptomatic infection. 
Mild or asymptomatic infection in young people is probably a major driver of the 
pandemic and human challenge studies are the only way to obtain data about how 
infection and viral shedding occur in this group. This will immediately affect policy 
on length of self-isolation and prioritisation for vaccines for these people, if we 
show that they are major shedders of virus. 
c) Determine how long people are infective. 
This human challenge study will allow us to accurately measure how long people 
are infectious, from first exposure to the virus being cleared. This will determine 
exactly how long self-isolation (quarantine) periods should be after exposure. 
d) Research risk of re-infection.  
Based on what we know from similar viruses, some people can catch COVID-19 
more than once. A human challenge study we are working on in Oxford will help 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
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answer a number of important questions on re-infection, including how long 
people are protected  after having had COVID-19; what makes people more at risk 
of re- infection; and whether re-infected people can spread the virus to others. 
e) Help vaccine development. 
 …, using challenge studies, the most promising vaccine candidates could progress 
much quicker, having been strengthened by early evidence of efficacy, and the risk 
of a large-scale trial failing would be minimised. In addition, the human challenge 
study would validate the impact of immune markers that correspond with 
protection, strengthening the licensure package. The flipside of this is that if a 
novel vaccine fails in a head-to-head study comparing with one of the current 
vaccines, then progression to a costly and burdensome phase III trial would be 
avoided. 
A key question that we will test for these vaccines is whether they stop people 
carrying and spreading the virus as well as preventing symptoms. Vaccines or 
antivirals that do nothing in healthy young adults are unlikely to work better in 
higher-risk populations (due to impaired immunity, kidney or liver function etc.), so 
can be de-prioritised in favour of those that do.” 
f) Help development of anti-viral treatments. 
This human challenge study will open the way for future testing of  these.  
g) Help manage variants 
With regard to variants and mutation, despite changes in the newer strains, it is 
also important to emphasise that fundamentally these are all the same type of 
virus and many findings about the disease and the immunology will be 
generalisable. In addition, most antiviral drugs target parts of the virus that have 
remained largely unchanged, so the value of rapid early testing of new treatments 
using the existing challenge virus is unlikely to be affected by strain variation in the 
near term. 
However, with unreliable transmission in the community, it may not be possible to 
test these quickly enough in field trials. In such an event, the human challenge 
programme will provide a simple and rapid method to test new vaccines against 
emerging strains. 
The next step is therefore to manufacture a new challenge strain that matches 
what manufacturers use to re-engineer their vaccines. With our experience, we can 
now produce a novel challenge agent more quickly than before but without this 
current study, human challenge development would have to start from scratch and 
testing of modified vaccines greatly delayed. 
In addition, follow-on studies (that will be subject to separate applications for 
ethical review) can give clear answers to questions that cannot be sorted out by 
field trials in a meaningful timeframe, including: 
• Whether new vaccines/vaccine regimes are as good as/better than existing ones 
o How to optimise the delivery of vaccines to ensure the most effective protection 
for the greatest number of people using one or two dose approaches can thus be 
resolved. 
o Testing vaccines adjusted for mutant viruses (variants) using human challenge in 
a “bridging study” could bypass the need for more phase III trials and allow 
emergency authorisation of updated vaccines. 
o  What protects people from re-infection after having previously had COVID-19.  
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o Very quick proof-of-concept studies are possible using human challenge that will 
bring these treatments on-line sooner. 
h) Identifying correlates of protection (i.e. the immune markers that are responsible 
for protection against SARS-CoV-2) is a powerful reason for running these studies 
in young adults as they are the benchmark for optimal immune responses. These 
can then be translated to higher-risk populations by immune bridging studies, 
where the immune markers that are shown to be responsible for protection in 
young adults can be used to accurately predict protection in higher-risk groups. 
i)  Contribute to pandemic management 
On its own, this study will provide answers with important short-to-medium term 
public health impacts, specifically: 
o Measuring virus coming out of the nose will show when and how 
much infectious virus is shed. 
o Only a challenge study can accurately measure asymptomatic 
infection. 
o Can the vaccine prevent asymptomatic infection? This could 
immediately alter public health strategy as it is considered that 
asymptomatic infection is driving the continuation of the pandemic.” 
 
iii. Have these questions been answered before? 
The committee accepted that, from the evidence presented, these questions had 
not yet been satisfactorily answered. 
iv. Will the chosen method and follow-on studies answer these questions (meet the 
stated purpose) and contribute meaningful information that will help disease 
prevention and treatment? 
The committee accepted expert opinion in support of this study and that proposed 
methods would answer the questions posed with regards to the aims in 1(ii) . 
v. Will results be applicable to the broader community (generalizability)? 
The committee debated the broader generalisability of study results when the 
volunteers were young, healthy and of low risk and wanted reassurance that this 
research would be relevant to the broader population. The applicants responded: - 
“While young healthy adults may not fully recapitulate high risk groups, they 
provide a benchmark for optimal protective immunity and are highly suitable for 
antiviral and monoclonal antibody testing. People in this age group are also likely to 
be the main drivers of continuing pandemic transmission once older adults are 
vaccinated.” 
vi. Has there been Independent review and review of prior work? 
The scientific quality of the research had been reviewed within the Sponsor's organisation, by 
the study team at hVIVO while two independent reports were provided. Further support was 
provided by the Dept of Health, Vaccine Task Force and the Wellcome Trust.  
vii. Has there been public involvement? 
See 3(ii) 
viii. Would the study detract from pandemic care? 
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Volunteers would be cared for, separately in the accredited isolation research unit 
at the RFH. For care of any volunteer who fell seriously ill see 2(ii). The committee 
asked whether the study should be timed to ensure that clinical care would be 
available should a volunteer fall seriously ill (i.e. Outside any surge of infection in 
the community).  See 2(iii). 
ix. How has transparency been ensured so results will be rapidly available? 
In line with the HRA transparency policy the committee wanted reassurance that 
the results would be openly available once the study was completed. The applicants 
responded: - 
“this is an academically-led study with the primary purpose of advancing scientific 
and medical knowledge.” 
 
2. Risks and benefits  
“It must be reasonable to expect that the potential benefits of SARS- CoV-2 
challenge studies outweigh risks.” 
Questions posed: 
i. What are the quantified risks? 
ii. Is care of volunteers acceptable including rescue medication? 
iii. Is the timing of the study acceptable?  
iv. Will viral containment meet current agreed standards? 
v. Is the quality of the infecting agent adequately ensured? 
vi. How are CT scans justified? 
vii. Are doses acceptable? 
viii. Are there a trial steering committee and Data Monitoring Committee? 
ix. Is payment to volunteers acceptable and not undue influence? 
x. Are compensation arrangements in place and acceptable? 
xi. Has expert review been satisfactorily conducted? 
xii. Has public consultation been undertaken? 
 
 
i. What are the quantified risks? 
Data presented to the committee:  
 Acute consequences:  
Age has been a major factor in severe outcome of COVID-19 in all series published 
so far (3). In one large meta-analysis by the Imperial group of data from China, it 
was estimated that the infection-mortality rate (95% confidence interval) in 20-29 
year olds was 0·0309% (0·0138–0·0923), and in 30-39 year olds was 0·0844% 
(0·0408–0·185) (4). Recent analysis of severe outcomes from several European 
countries using denominators estimated by seroprevalence data showed the 
following in young adults <30 years old. 
• Risk of death following infection: 1.2-6.1 per 100,000 (0.0012-0.0061%) 
• Risk of ICU following infection: 0.9-4.5 in 10,000 (0.009-0.045%) 
• Risk of hospitalization following infection: 0.8-3.9 per 1,000 (0.08-0.39%) 
Data from the Office of National Statistics UK from the 16 weeks between 7th 
March and 26th June 2020 covering the peak of the first pandemic wave show an 
estimated absolute risk of death in those aged 15-24 years of 0.5 in 100,000 
(0.0005%) and those aged 25-34 of 1.6 in 100,000 (0.0016%).  
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Additionally, the qCOVID living risk prediction algorithm provides an absolute risk of 
COVID-associated hospitalization in a White British 30 year old woman with no risk 
factors as 1 in 5076 (0.0197%). 
 Ethnicity and acute consequences 
The applicants’ public and participant inclusion and engagement as well as reviews 
by experts in BAME health highlighted two opposing views: (1) that inclusion and 
diversity should be maximized, and (2) that BAME people should not be subjected 
to any increased risk before those with no documented risk had been through the 
study procedures.  
“To take these views into account and since this increase in risk was not identical 
across ethnicities, it was felt that a regularly updated personalised risk assessment 
(qCOVID) would be a better way to balance inclusivity with safety. “ 
 Long-term complications of COVID-19.  
Data from the COVID Symptom Study (King’s College London, September 2020, 
personal communication, Claire Steves) using self-reported symptom data from a 
mobile phone app to analyse the frequency and duration of symptoms related to 
COVID-19 shows that in 629 individuals in the 18-30 year old age group with PCR-
confirmed SARS-CoV-2 infection and who were non-smokers, had a BMI<25, had no 
co-morbidities and consistently logged into the app. The most frequent symptoms 
were fatigue (78%), headache (74%), loss of smell (61%), sore throat (59%) and 
cough (48%). On average, these symptoms lasted no more than 5 days although 
some rare individuals experienced loss of smell and fatigue for up to 4 months 
before resolution. Nevertheless, fatigue had resolved in 75% of individuals after 11 
days or fewer and 90% of individuals after 19 days or fewer, and loss of smell in 75% 
after 9 days or fewer and 90% after 14 days or fewer. Further analysis of the overall 
dataset has allowed the development of a risk prediction system for “long COVID”, 
which has shown relatively lower risk in younger individuals with <5 symptoms (5). 
ii. Is care of volunteers acceptable including rescue medication? 
The committee was satisfied by detail provided and further reassured that, should a 
volunteer become seriously ill, care would be available at the Royal Free Hospital 
with its ITU facilities.  
The committee was particularly concerned about the off license use of Remdesivir 
as rescue therapy, given there was no clear evidence of benefit in similar groups. 
This possible value was extrapolated from animal work and there was no human 
data on this pre-emptive use. The applicants provided hypothetical reasons to 
support this and responded: - 
“The investigators remain convinced of the need to administer early treatment with 
Remdesivir as an additional safety measure, at least during the initial dose 
escalation phase. As there is currently no data on clinical outcomes of low-dose viral 
challenge in this setting, we are taking a highly conservative approach during these 
early cohorts. Remdesivir has been shown to be an extremely safe and well-
tolerated drug. Phase I clinical trials of Remdesivir (which were carried out in the 
young adult age group) showed that the drug was safe even at much higher doses 
than the current standard of care and no safety issues associated with Remdesivir 
have been observed in any placebo-controlled trials to date. 
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..from published data we conclude that Remdesivir treatment will cause little harm 
and may limit lung involvement, if this were to occur in the controlled infection 
setting.” 
iii. Is the timing of the study acceptable? 
The committee queried whether it would be more appropriate to carry out the 
research after Spring 2021 given current pressure on ITU facilities, feeling that 
contingencies must be established to provide for clinical capacity in case a 
participant became unwell while the care of NHS patients must not be 
compromised. The applicants responded: - 
“Procedures have been solidified to make sure there is clinical capacity to take care 
of our study participants in case they need rescue therapy. A panel of leaders of the 
North Central London (NCL) Adult Critical Care Network advise that CRITCON levels 
may not provide the resolution needed to address this concern and instead 
suggested that the Chief Investigator, Principal Investigator and clinical team seek 
their approval before initiation of each challenge group as follows: 
• Using their direct access to daily capacity data across the network, plus local and 
national projections, …the panel will provide an evidence-based opinion on clinical 
capacity at the start of each challenge group as well as the weeks to come and 
advise whether it is safe to commence. 
• This will also include review of non-ITU bed state and radiology capacity. 
• This decision will be recorded in the Trial Master File and no dosing will take place 
without a favourable opinion from this panel. 
This process has been adopted.” 
iv. Does viral containment meet current agreed standards? 
The committee accepted that this would be run in an established, accredited 
isolation unit with appropriate precautions and facilities.  
v. Is the quality of the infecting agent was adequately ensured? 
The committee received a Qualified Person (QP) declaration for the challenge virus, 
which explained that the QP had reviewed the challenge virus documentation and 
confirmed its compliance with the principles of GMP (GMP itself cannot be applied). 
Further: - 
“We agree that it is best practice to manufacture challenge viruses to GMP. We can confirm 
that our challenge virus has been manufactured in accordance with GMP in a state-of-the-art 
brand new high containment manufacturing facility. The specific manufacturing process and 
release testing of the SARS-CoV-2 challenge virus have been reviewed by the MHRA and 
confirmed suitable.” 
vi. How is the use of CT scans justified? 
The committee queried the role and value of the CT scans and their associated 
radiation dosage. The applicants responded: - 
“the CT scan was included in the model to assess whether the infection of young 
adults using this system would lead to pulmonary changes. It was expected that 
most participants would have a mild form of the disease and therefore there would 
be no lower airway changes, however it there were some changes the team would 
need to consider whether it was appropriate to continue using the model; this would 
be another read out to assess safety.  
Involvement of the lungs during COVID-19 is one of the most important measures of 
disease severity in patients …The only way to objectively measure lung involvement 
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in COVID-19 is by radiology… Chest X-ray is not sensitive enough to detect mild 
changes in patients…CT scan is therefore the only way to detect these lung changes 
and two scans are necessary to pick up all instances as they can appear both early 
and late. 
Lung changes may predict symptoms and the model may be made safer by 
prevention of lung changes e.g., by retaining pre-emptive therapy or reducing virus 
dose 
.. we have been able to further reduce the radiation dose of each CT scan by 50%. 
This means that participants will at most be exposed to ~3mSv even with two CT 
scans.” 
vii. Are proposed doses acceptable? 
The committee accepted expert advice on this. 
viii. Is there a trial steering committee and Data Monitoring Committee? 
The committee accepted details on this. 
ix. Is payment to volunteers acceptable? 
The applicants wrote that: - 
“the usual compensation calculation based on the London Living Wage and time 
spent in the unit would be provided.” 
The committee accepted the principle of payment and felt the level of 
remuneration was fair. 
x. Are compensation arrangements acceptable? 
The volunteers would be expected to contract COVID 19 and suffer some symptoms 
and symptoms. Compensation would have to cover adverse events beyond these 
minor symptoms and signs while in the isolation unit. The applicants replied 
“along with additional compensation for longer term effects the sponsor had taken 
out an additional insurance policy to cover for potential practical disruptions to 
normal life and potential loss of earnings. Participants would be at liberty to claim 
for this if any issues were experienced.” 
xi. Has expert review been satisfactorily conducted? 
See 3(i). 
xii. Has public consultation been undertaken? 
See 3(ii). 
 
3. Consultation and engagement  
“SARS-CoV-2 challenge research programmes should be informed by consultation 
and engagement with the public as well as relevant experts and policy- makers.” 
Questions posed: - 
i. Has expert independent review been sought? 
ii. Has public consultation been undertaken and is this appropriate to the needs of the 
ethnic population (BAME)? 
Questions and deliberations 
i. Has expert review been sought? 
The applicants replied.  
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“The Vaccine Taskforce Human Challenge Board, chaired by the Deputy Chief Medical 
Officer, includes members from government, Wellcome Trust, MRC and leading 
universities, including members of the Joint Committee for Vaccination and Immunisation 
(JCVI). They continually engage with a strong collaborative network of global experts 
(including University of Oxford, Royal Free, UCL, Imperial, University of Southampton, 
hVIVO and WHO Advisory Group on Human Challenge).  
ii. Has public consultation been undertaken and is this appropriate to the needs of 
the ethnic population (BAME)? 
The applicants wrote: - 
“An extensive programme of public engagement was conducted to support the development of this 
study. This comprised a survey of 2,137 people through YouGov, targeted survey of 350 people and 9 




 October 2020. 
The wide-reaching survey showed that there was overall agreement that a human challenge study 
with coronavirus should take place in the UK, but flagged practical concerns related to quarantine 
(which will be carefully explained to potential participants during the consent process). Many felt that 
the health risks to young people were small and un-concerning, the societal benefits outweigh the 
risks and they would feel positive contributing to science. 
Some common points of discussion included needing clear and detailed explanation of the risks; 
concerns about long COVID; worries about needing time off work or being able to work effectively 
from the unit; mental health consequences; and protecting vulnerable people. Each of these will be 
addressed specifically during the consent process.  
Further study specific PPI was then carried out, including a focus group with individuals from BAME 
backgrounds, where the risk profile and perceived risk of participation were discussed. 
A focus group involving individuals who had taken part in previous challenge studies looked 
at consent processes. A draft version of the information sheet had been reviewed by this 
group and feedback had been provided. 
Public engagement activities will continue, and a communication strategy is being 
developed between Imperial, hVIVO, Royal Free Hospital and the funder.” 
See also 2(i) and 6(i). 
4. Coordination  
“SARS-CoV-2 challenge study research programmes should involve close 
coordination between researchers, funders, policy-makers and regulators.” 
Question and deliberation 
i. Has there been engagement with government and regulators? 
The applicants wrote: - 
“the team had been engaging with the MHRA about where human challenge data would fit 
in in terms of new vaccines along with reengineered vaccines…The Vaccine Taskforce Human 
Challenge Board, chaired by the Deputy Chief Medical Officer, includes members from 
government, Wellcome Trust, MRC and leading universities, including members of the Joint 
Committee for Vaccination and Immunisation (JCVI). They continually engage with a strong 
collaborative network of global experts (including University of Oxford, Royal Free, UCL, 
Imperial, University of Southampton, hVIVO and WHO Advisory Group on Human Challenge). 
“ 
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5. Site selection  
“SARS-CoV-2 challenge studies should be situated where the research can be 
conducted to the highest scientific, clinical and ethical standards.” 
Questions posed: - 
i. Is site selection satisfactory and facilities appropriate? 
ii. Do the applicants have the necessary expertise and experience?  
iii. Does the team work under appropriate legal, institutional, and professional 
accountability? 
Questions and deliberations  
i. Is site selection satisfactory and facilities appropriate? 
The study would be conducted in a unit equipped for handle such an infecting agent (The 
Royal Free Hospital, London) and this was accepted.  
ii. Do the applicants have the necessary expertise and experience?  
The applicants wrote: - 
“The collaborative team we have formed for this study combines viral challenge study 
experts from academia, industry and government that are collectively among the most 
experienced viral challenge team worldwide. 
For example, just hVIVO and Imperial combined have safely inoculated over 4000 people 
with influenza virus, Respiratory Syncytial Virus and Human Rhinovirus with populations 
covering both healthy adults aged 18-74 and asthmatics.” 
iii. Does the team work under appropriate legal, institutional and professional 
accountability? 
These were described and the committee accepted the answers provided. 
 
6. Participant selection  
“SARS-CoV-2 challenge study researchers should ensure that participant selection 
criteria limit and minimize risk.” 
Questions posed:  
1. Are participants at least risk? 
2. Is there fair selection? 
3. Is there fair approach to volunteers? 
4. Is there assessment of physical and mental health? 
5. Is there contact with the Health Care Practitioner? 
6. Is there protection against over volunteering?  
Questions and deliberations  
i. Are participants at least risk? 
See also 2(i).  
The applicants wrote: 
“,it was felt that a personalised risk assessment (QCOVID) would be the best way to balance 
inclusivity with safety and the recruitment approach should be responsive to the most up-to-
date data.” 
Given the advice that QCOVID was not recommended for individual clinical decisions, the 
committee debated this and discussed it with the researchers. It was agreed ultimately that, 
despite this advice, QCOVID was the most suitable instrument. 
ii. Is there fair selection? 
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The committee believed that there should be risk based selection with  no unfair 
discrimination but understood that current evidence was that those of  BAME origin were at 
some increased risk.  In discussion the committee accepted that the analysis by the Office of 
National Statistics and the OpenSAFELY  https://www.opensafely.org/ and ISARIC 4C studies 
(https://isaric4c.net/) of hospitalized patients have all concluded that the majority of the 
increased risk seen (particularly in Black and South Asian groups) was related to 
socioeconomic factors including greater exposure due to disproportionately being in front-
line jobs. However, there remained some element of increased risk in BAME individuals that 
was still unexplained. The applicants reported: - 
“ public and participant inclusion and engagement as well as reviews by experts in BAME 
health highlighted two opposing views: (1) that inclusion and diversity should be maximized, 
and (2) that BAME people should not be subjected to any increased risk before those with no 
documented risk had been through the study procedures. To take these views into account 
and since this increase in risk was not identical across ethnicities, it was felt that a 
personalised risk assessment would be a better way to balance inclusivity with safety and 
the recruitment approach should be responsive to the most up-to-date data. The QCOVID 
risk scoring tool is an independent, validated risk assessment algorithm that integrates age, 
sex, ethnicity, geography, body mass index and co-morbidities to provide an individualised 
estimate of absolute mortality and hospitalisation risk. This provides an objective absolute 
risk of death and hospitalization based on the best available UK epidemiologic data. The tool 
is CE marked and will be recalibrated with up-to-date data every 3-6 months. 
By setting a risk threshold, the potential risks associated with particular participant features 
(such as ethnicity, sex or BMI) may be balanced holistically and certain risk factors mitigated 
by other characteristics such as younger age). 
iii. Is there fair approach to volunteers? 
This had been reviewed and approved at a prior meeting. 
iv. Is there assessment of physical and mental health? 
This was reviewed and the proposed methods accepted. 
v. Is there contact with the Health Care Practitioner (HCP)? 
This was reviewed and agreed would be an important part of mitigating risk. Changes to the 
correspondence with the HCP were requested. 
vi. Is there protection against over volunteering?  
The TOPs over volunteering database that would identify previous enrolment into phase I 
clinical studies would be used: https://www.hra.nhs.uk/about-us/committees-and-
services/the-over-volunteering-prevention-system/ 
 
7. Expert review  
“SARS-CoV-2 challenge studies should be reviewed by a specialized committee.” 
The members of this committee were from Research Ethics Committees in the UK 
recognised to review both Clinical Trials of Investigational Medicinal Products (CTIMPs) and 
Phase 1 studies in healthy volunteers. Selection also focussed on those with experience of 
vaccine studies. Membership ensured a balance of expert and lay members in accordance 
with the relevant legislation and guidance and representation across the four nations. 
Those appointed to the committee were invited to two remote workshops on HICS 
conducted on Zoom and provided a current reading list. The committee also had access to 
other expertise and resources. 
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8. Informed consent:  
“SARS-CoV-2 challenge studies must involve rigorous consent processes.” 
Questions posed: - 
i. Is there a framework of consent processes? 
ii. Are volunteers presented with the clear key facts? 
iii. Is the consent interview recorded? 
iv. Is there an assessment of understanding? 
v. Is there fair time for consent?  
vi. Do those seeking consent have appropriate expertise and training?  
vii. Has there been public Involvement in consent processes?  
 
Questions and deliberations  
i. Is there a fair framework of consent processes? 
A schedule was provided and accepted. 
ii. Are volunteers presented with the clear key facts? 
A Key Fact Summary sheet to introduce the study was developed and accepted.  
iii. Is the consent interview audio or video recorded? 
This was a suggestion made by the committee and accepted.  
iv. Is there an assessment of understanding? 
The committee was reassured by  
 Use of a Key Fact Summary Sheet 
 An improved PIS 
 A break in procedures for volunteers to discuss the possibility of 
volunteering with others. 
 An itemised Informed Consent Form referring to “key facts”. 
 An MCQ  quiz (that had to be passed) to assess understanding . 
v. Is there fair time for consent? 
The committee was reassured on this. 
vi. Do those seeking consent have appropriate expertise and training?  
This was presented and accepted.  
vii. Has there been public Involvement in consent processes?  
The Participant Information Sheet (PIS) and Informed Consent Form (ICF) had been 
submitted for broader comment (see also 3(ii)). We accepted that these groups thought it 
to be of good quality, the right length and level of detail and recommendations had been 
acted upon. Further advice was offered by one committee member. 
 
 
9. Evaluating alternative study design1 
Questions posed: - 
i. What alternative designs might answer the research questions and meet the 
research purpose? 
                                                          
1
 Not a WHO category but the committee felt this of vital importance and would 
recommend its addition.  
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ii. Why should the study be conducted in the UK? 
 
i. What alternative designs might answer the research questions and meet the 
research purpose? Couldn’t field studies (investigating naturally acquired 
infection) provide answers to the research questions?  
The committee understood that as infection rates fell, field studies would be more time 
consuming and difficult but looked into the exact data that different studies would generate 
and how each would link to the aims of prevention and treatment of SARS COV 2 infection. 
The applicants responded: -  
“Field studies are slow, expensive and complicated by differences in the populations in which 
they are carried out. Controlled direct head-to-head comparisons to compare new vaccines 
against existing ones are only feasible using human challenge. Furthermore, even with 
limited vaccination, pandemic waves will wax and wane unpredictably in those regions due 
to factors such as seasonal changes and public health measures. As a result, many more 
volunteers will need to be immunised with a vaccine candidate of unknown efficacy in a field 
trial than a challenge study (exposing more people to risk) and results will be much slower to 
obtain. 
In addition, questions have been raised about the ethics of running vaccine trials in low and 
middle income settings (LMICs) for the benefit of more wealthy countries. This has proven 
highly problematic with some local communities, who have been concerned about 
exploitation, quality of study conduct, and uncertain benefit to themselves. 
Importantly, where a vaccine has already been shown to be safe and effective in a phase III 
study, human challenge studies can also be used to quickly bridge when the vaccine is 
reformulated either in response to viral mutation or, for example, changes in manufacturing 
to improve supply chain. Thus, emergency use authorisation could be given to a 
reformulated vaccine after a rapid, small challenge study (as has been done recently with 
the conjugated typhoid vaccine).” 
The committee accepted this position. 
ii. Why should this study be located the study in the UK?  
The applicants answered: - 
“we believe that it is essential to run this first ever SARS-CoV-2 human challenge study in the 
UK as it is the only place with the facilities, expertise, experience and coordinated approach 
necessary to establish the model safely. The collaborative team we have formed for this 
study combines viral challenge study experts from academia, industry and government that 
are collectively among the most experienced viral challenge team worldwide. However, 
having established the safety profile, required virus dose and suitable endpoints to monitor 
infection, challenge models for all subsequent use can be set up, including potentially in 
other countries. 
Based on our experiences setting up challenge studies in low- and middle-income countries 
(LMICs), it has only been possible to obtain public support and ethical approval to extend 
these studies once the model had been shown to be safe in a high-resource setting such as 
the UK” 
The committee accepted this position. 
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